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AMERICAN DEPOSITARY RECEIPTS:
AN OVERVIEW
Joseph Ve~li*
INTRODUCTION
I would like to thank everybody involved for providing me
with this opportunity to speak to you about the wonderful world
of American Depositary Receipts ("ADRs"). Today I will attempt
to provide you with an overview of the ADR market. I will talk
about the different types of ADR programs available, and I will
talk about the growth that has occurred over the last several
years.
Before I start, though, I thought it would be useful to set the
stage a little bit. I just want to mention a few points. As Bill
Decker mentioned earlier,1 for the first time, last year Glaxo, a
non-U.S. company out of the United Kingdom, was the most ac-
tively traded stock on the New York Stock Exchange ("NYSE").
That, in and of itself, is very impressive. About 275 billion Glaxo
ADRs were traded on the NYSE traded last year. But what I
think is more impressive is that over 350,000 U.S. investors own
Glaxo ADRs, and Glaxo's market capitalization here in the
United States is approximately U.S.$20 billion. So the trading
volume is impressive, but so is the number of shareholders and
their market capitalization.
It is also important to realize that, excluding Canadian com-
panies, the vast majority of non-U.S. companies use ADRs when
they decide to list in the United States. In fact, some of these
companies are more actively traded in the United States than in
their home country. For example, for Hong Kong Telecom out
of Hong Kong, Repsol out of Spain, Telemex out of Mexico,
there is more trading volume both in share terms and in dollar
* Executive Vice President, The Bank of New York, New York, N.Y.; B.A., William
Paterson College; M.B.A., Fairleigh Dickenson University. Mr. Velli established The
Bank of New York's Depositary Receipt business in 1984. He is a member of the Inter-
national Operations Association and the Securities Industries Association.
1. See William E. Decker, The Attractions of the U.S. Securities Markets to Foreign Issuers
and the Alternative Methods of Accessing the U.S. Markets: From the Issuer's Perspective, 17
FoRDHAm INT'L L.J. S1O (1994) (discussing increased attraction of non-U.S. companies
to U.S. capital markets and options available accessing into those markets).
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terms in the United States than in their respective home coun-
tries.
I. ADRs: GENERAL BACKGROUND
A. Operation of ADR Programs
What are ADRs? How do they work? Very simply, an ADR is
a receipt that is issued by a U.S. depositary bank, such as The
Bank of New York, that actually represents the shares that are
held overseas. So the ADR is merely a receipt that is issued in
certificate form in the United States that represents the actual
shares of a non-U.S. company.
Once the ADR program is established, the ADRs trade freely
in the United States, like any other U.S. security. They can trade
on the over-the-counter market or they can trade on one of the
exchanges, such as NASDAQ the American Stock Exchange
("ASE"), or the NYSE. ADRs can also be used to raise equity
capital.
I think one recent trend is that people have gotten away
from calling depositary receipts "American depositary receipts."
Now, they basically either call them "global depositary receipts"
("GDRs"), or simply, as I prefer, "depositary receipts." In order
not to confuse anybody, though, I will use the most common
term, "ADRs."
The best way to understand how an ADR works is to look at
an example of a trade. Again, let's go back to Glaxo, which
trades on the NYSE. Glaxo did not raise capital here; the com-
pany simply listed on the NYSE without conducting a public of-
fering.
Let's assume that the very first trade takes place here in
Glaxo's ADRs. A U.S. investor, whether it's an institutional inves-
tor or a retail investor, would simply call up his U.S. broker and
say, "Buy me 1,000 or 10,000 Glaxo ADRs." In many cases the
investor is not even aware that he is buying an ADR; all he really
knows is that he's investing in Glaxo. So he calls up his broker
(for argument's sake Merrill Lynch or Goldman Sachs) and says,
"Buy me 1,000 Glaxo ADRs."
The broker, because there are no ADRs outstanding here,
goes to the foreign market, in this case the London market, buys
1,000 Glaxo shares off the London exchange, deposits those ac-
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tual shares with the depositary bank (for example The Bank of
New York) and then the depositary bank issues 1,000 ADRs in
the U.S. marketplace. So the shares are deposited by the broker
and The Bank of New York would issue 1,000 ADRs. That's how
an ADR is created.
Once the ADR is issued and outstanding, it freely trades like
any other security. In the very next trade, if another investor
calls up his broker and says, "I want to buy 500 Glaxo ADRs," the
broker has a choice: he can either buy the ADR that is already
existing in the U.S. marketplace, or he can repeat the process
just described by going to the London Stock Exchange.
The last point on the trading aspect is what we call ADR
cancellation. If I own 1,000 Glaxo ADRs and want to sell those
ADRs, but cannot find a buyer, I simply would cancel those
ADRs and sell the actual shares back into the home market, in
Glaxo's case, in London. Thus, ADRs can be created or issued,
they can be transferred here like any other U.S. security, or they
can be canceled.
B. Rationale Behind Establishing ADR Programs
There are several different reasons why non-U.S. companies
establish ADR programs. Some of them were covered today and
I will not harp on them. Basically, companies establish ADR pro-
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grams as a way of entering the U.S. markets to, hopefully, tap
some demand for their securities. Many companies have found
that by establishing ADR programs and enabling U.S. investors
to buy their ADRs, they are able to get a better valuation for
their share price. There are a couple of reasons for this.
First, in many industries or many sectors here, such as the
telecommunications sector, the U.S. investment community may
put a higher valuation or price/earnings ratio ("P/E") on that
sector. As a result, if you are a company in France and you're in
the telecommunications business and your P/E in France is 14
and the P/E in the United States for telecom stocks is some-
where around 18, by establishing an ADR program you should
receive a higher valuation for your shares.
Second, the simple fact of a non-U.S. company establishing
an ADR program here, enabling U.S. investors to buy the shares
simply here, usually translates into a higher stock price for the
company.
Third, companies establish ADR programs as a means of
raising capital in the United States. In many cases, when a com-
pany is making an offering, their home market cannot absorb it
- for example, YPF, an Argentine oil company, earlier this year
did a U.S.$3 billion global offering that was part of a privatiza-
tion. There was no way YPF was going to be able to raise U.S.$3
billion in the Argentine market. As a result, they raised roughly
U.S.$500 million locally, they raised U.S.$2 billion in the United
States, and U.S.$500 million in Europe.
Companies also establish ADR programs for other reasons.
A great example is Roche, the Swiss pharmaceutical company.
Roche established an ADR program for one reason: they have
about 40,000 U.S. employees who wanted to invest in the parent
company. By establishing an ADR program, the company was
able to give their executives in the United States stock options, it
was able to offer a 401-K savings plan for their U.S. employees,
and the program enabled the U.S. employees to buy Roche
ADRs.
C. Investor Perspective
From the investor's standpoint, U.S. investors buy ADRs for
three main reasons: convenience, cost, and liquidity. From the
convenience side, ADRs trade and settle just like any other U.S.
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security. There is no difference between buying Glaxo ADRs
and buying IBM, AT&T, or General Motors stock. It works ex-
actly the same way, you pay the same commission rates. ADR
dividends are paid in U.S. dollars and they settle just like any
other U.S. security. So there is virtually no difference between
buying and selling an ADR and buying and selling any other U.S.
security.
On the cost side, ADRs also offer a lot of advantages as com-
pared to what we call "direct" investing, meaning buying Glaxo
shares directly in the U.K. market. There are three major cost
advantages from a U.S. investor's standpoint.
First, custody fees are avoided. If I buy Glaxo shares in
London, or an institution buys them in London, you have to ap-
point a global custodian to hold the shares in London. That
global custodian could charge you anywhere from ten to forty
basis points annually. By buying an ADR, which settles and
clears in the United States, U.S. investors avoid that charge.
Second, foreign exchange rates on dividends are better on
ADR dividends. Typically, when the depositary bank pays divi-
dends and converts, in Glaxo's case Pound Sterling, into U.S.
dollars, because we are converting such a large sum of money,
we are able to get a better rate than if you as an investor went to
your bank and tried to cash a £10 cheque. So the foreign ex-
change rates are better in dividends.
Third is what I call "failed trade financing." Because ADRs
settle according to U.S. principles and they settle in the United
States, very rarely does a trade fail. What I mean by "fail" is if an
investor buys the ADRs and they are not delivered on the settle-
ment date, resulting in the failure of the trade. The failed trade
rate in the United States for ADRs is less than 0.5%. If an inves-
tor buys shares directly in places like Brazil, Chile - not so
much in Latin American anymore; they've straightened it out -
but still in places like Italy, Spain, China, the failed trade rate
could be substantially higher. As a result, the investor would
have to finance his position, and that cost could add up over
time.
[Vol. 17:S38
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II. ADR PROGRAMS
Raise
Type Act Registration Disclosure Cost Listing a
Unsponsored 1933 F-6 None 0 OTC No
1934 12G3-2(b) None
Sponsored 1933 F-6 None $ 5,000 OTC Not Now
Level I 1934 12G3-2(b) None $ 20,000
Sponsored 1933 F-6 None $200,000 Exchange Not Now
Level II 1934 20-F Detailed $500,000
Sponsored 1933 F-i Rigorous $400,000 Exchange Yes - U.S.,
Level III 1934 20-F Detailed $900,000 Global
Private 1933 None Euro- $100,000 Portal Yes - U.S.,
DR 1934 12g3-2(b) Style $400,000 Global
A. Unsponsored ADR Programs
There are essentially two types of ADR programs: unspon-
sored and sponsored. I am not going to spend a lot of time on
unsponsored ADRs. The key thing to remember about unspon-
sored ADRs is they are absolutely obsolete, and there are a lot of
hidden costs and problems associated with unsponsored ADRs.
In fact, since 1983, there have only been three new unsponsored
ADR programs established.
B. Sponsored ADR Program
What has taken their place is what we call sponsored ADRs.
Simply, the word "sponsored" means that the company is ap-
pointing a U.S. depositary bank and the company is sponsoring
their entry into the U.S. capital markets. As a result, there is a
service contract in place and the investor can be relatively as-
sured of the type of service and information they are going to
receive on an ongoing basis.
1. Level I, II, and III ADR Programs
There are essentially three types of sponsored ADRs: Spon-
sored Level I, Level II, and Level III.
A Sponsored Level I ADR trades over-the-counter in the
United States on the pink sheets. You establish a Level I pro-
gram by establishing what is known as an information exemp-
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tion2 under the Securities Exchange Act of 1934 (the "Exchange
Act").3 Basically, all a company has to do is supply the Securities
and Exchange Commission ("SEC") with any material informa-
tion they produce and distribute locally in their home country
and they can obtain an exemption from registration.4
A Level I program, because the company is not registered
fully with the SEC, cannot be listed on an exchange and a Level I
program cannot be used to raise capital. However, many compa-
nies have found that by establishing a Level I program, because
it's very easy to do and is a low-cost way of entering the U.S.
market, they use it as their first step into the U.S. public markets.
They establish a Level I program, they start an investor relations
exercise, and they start building up a core group of U.S. inves-
tors.
Level II is when a company decides to list on one of the
exchanges. In order to list on one of the exchanges you have to
file a Form 20-F5 under the Exchange Act, which again means
essentially complying or reconciling to U.S. accounting and dis-
closure requirements. For some companies this could be costly
and difficult; for other companies it shouldn't be a problem.
Level III ADRs is when a company decides to make a public
offering in the U.S. marketplace. Typically, as was discussed to-
day, this requires filing a Form F-1 with the SEC,6 which again
requires complying with U.S. accounting and disclosure proce-
dures.
We have found, over time, that the vast majority of compa-
nies that come into the U.S. market start off with a Level I ADR
program and then upgrade over time. The upgrading could
take anywhere from six months to ten years, but eventually com-
panies with Level I programs upgrade to either a listing on the
NYSE, the ASE, or NASDAQ.
In fact, Glaxo is a prime example. The company started
out with a Level I program that lasted for approximately one
2. Exchange Act Rule 12g3-2(b), 17 C.F.R. § 240.12g3-2(b) (1993).
3. 15 U.S.C. §§ 78a-7811 (1988 & Supp. IV 1992).
4. Exchange Act Rule 12g3-2(b), 17 C.F.R. § 240.12g3-2(b); see Mark A. Saunders,
American Depositary Receipts: An Introduction to US. Capital Markets for Foreign Companies,
17 FORDHAm INT'L L.J. 48, 76-77 (1993) (setting out Rule 12g3-2(b) exemption require-
ments).
5. 17 C.F.R. § 249.220f (1993).
6. 17 C.F.R. § 239.31 (1993).
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year. It was able to build up a core group of U.S. investors.
Eventually Glaxo upgraded to the NYSE.
If I could just mention one other point on listing, our posi-
tion, and what we usually recommend to companies, is that they
should not get too excited about a Level I program. Their man-
agement must fully realize that it's only a starting step and their
visibility, unless they have an unbelievably good story to tell U.S.
investors, is going to be very limited. Typically, a Level I com-
pany can expect to obtain anywhere between three to six percent
of its shareholder base in the United States through such a pro-
gram. What we have found is that when they do a listing and
they upgrade it, whether they do a Level II or Level III, their
U.S. investor base will materially increase. If a company has four
percent U.S. shareholder base with a Level I, they could expect
somewhere between ten to fifteen percent with a Level III.
2. Common Misconceptions
As Bill Decker mentioned this morning,7 we typically run
into a lot of misconceptions or misinformation in the market-
place. Many companies do not realize that there are different
types of ADR programs. Some are very easy to establish, some
are more difficult because of accounting and legal issues; some
are very cheap to establish; and some cost significant amounts of
money.
The biggest misconception right now in the marketplace is
that there is a difference between ADRs and GDRs. There is ab-
solutely no difference between an American Depositary Receipt
and a Global Depositary Receipt. They work exactly the same
way. What will happen is with a Level III ADR or with a private
placement under Rule 144A of the Securities Act of 1933 ("Rule
144A" or "144A"),' the underwriter will determine what to call
the depositary receipt. If a big portion of the offering is taking
place in Europe, the underwriter will call the depositary receipt
a GDR, trying to get away from tainting the security by calling it
an "American Security." If the majority of the offering takes
place in the United States, then the underwriter will call it an
ADR.
7. See Decker, supra note 1, at S10 (noting misconceptions non-U.S, companies
have concerning registration of securities in United States).
8. 17 C.F.R. § 230.144A (1993).
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3. Growth of the ADR Market
Regarding the growth of the market, at the end of 1993, we
are projecting that there will be approximately 990 ADR pro-
grams. Over the course of 1993, we are projecting that about
110 new ADR programs will be established. The reason why the
numbers for 1992 and 1993 don't match up is that a lot of com-
panies are obviously converting from unsponsored to sponsored
and some companies go through mergers, bankruptcies, and
other reorganizations. But from 1992 to 1993 we are projecting
that over 110 new companies will establish ADR programs, which
will be a record.
TOTAL NUMBER OF PROGRAMS
AS OF JUNE 30, 1993
700
1986
836
1990
886
1991
924
1992
*990
953
1993
*Year-end projection
mIncludes all Depositary Receipt programs except 144A Depositary Receipt programs
The largest ADR markets are the United Kingdom, Austra-
lia, and Japan. These three markets represent approximately
half of the ADR marketplace. What is of interest is that over the
last three years, the fastest growing part of the world for ADR
programs in terms of percentage has been Latin America. It
started off in Mexico three years ago, and now it has spread to
Argentina, Brazil, Chile, Peru, and Colombia. Latin America,
[Vol. 17:S38
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for the last three years, has clearly been the fastest-growing seg-
ment of the ADR market.
PERCENTAGE OF TOTAL DEPOSITARY RECEIPT
PROGRAMS BY COUNTRY AS OF JUNE 30, 1993
As of June 30, 1993 there were 953 Depositary Receipt programs
2.5%
Y Germany 2.5%
Netherlands 2.5%
U.K. France 2.7%
22% .,
Ho Kong
........... 
07.5%
South Africa
9.1%
Austrailia
!8.2% ,f
S 4 /42 ' c":':. Japan
15.5%
Other
17.3%
N Excludes 144A Depositay Receipt pmgrun
Going forward, we expect that, for the next few years, Latin
America will remain one of the fastest-growing, but we expect
Southeast Asia to eventually overtake Latin America. In fact, ear-
lier this year, Shanghai Petrochemical was the first company out
of China to do an ADR offering and listing on the NYSE. We
expect that, within the next eighteen months, somewhere be-
tween twelve to twenty companies from China will have ADR
programs here. In fact, we are currently working on four ADR
programs for Chinese companies. Hong Kong is also another
fast growth market for ADRs. Out of the top fifty companies in
Hong Kong, forty-three have ADR programs, all of which have
been established over the last year.
We are projecting that, by the end of 1993, there will be
about 251 companies with ADR programs listed here on one of
the exchanges. The majority of these companies are listed on
the NYSE. Again, the type of ADR program that is used to list on
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TOTAL NUMBER OF LISTED DEPOSITARY RECEIPT
PROGRAMS ON NYSE, AMEX AND NASDAQ
AS OF JUNE 30, 1993
*251
231
215
186
176
116
1986 1990 1991 1992 1993
*Year-end projection
an exchange is either a Level II or a Level III ADR. In order to
list, as was discussed by Bill Decker and Frode Jensen, essentially
you have to comply with U.S. accounting and disclosure stan-
dards, just like any other U.S. company would.9
There are a couple of reasons for the rapid pick-up in list-
ings. One is, many companies that established Level I programs
two or three years ago had a very favorable experience in the
U.S. marketplace and are now upgrading to a listing on an ex-
change. The second reason is that many companies are simply
coming into the market, skipping Level I and Level II ADRs, and
doing public offerings straight-away to take advantage of the
favorable market conditions that exist today.
For 1993, we are projecting about U.S.$182 billion worth of
ADRs will trade here on one of the exchanges. That is up signifi-
cantly compared to 1992, when U.S.$125 billion worth of ADRs
traded. There are a couple of reasons for this. First, which is
9. See Decker, supra note 1, at S10 (discussing increased attraction of non-U.S.
companies to U.S. capital markets and options available for accessing those markets);
Frode Jensen, III, The Attractions of the U.S. Securities Markets to Foreign Issuers and the
Alternative Methods ofAccessing the U.S. Markets: From a Legal Perspective, 17 FoRDHAm INT'L
L.J. S25 (1994) (discussing alternative methods for non-U.S. companies to access U.S.
capital markets); see also Regulation S-X, 17 C.F.R. § 210.4-01(a)(2) (1993) (requiring
either complying with U.S. GAAP or reconciling with U.S. GAAP).
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ANNUAL DOLLAR VOLUME OF DEPOSITARY RECEIPTS
LISTED ON NYSE, AMEX AND NASDAQ (TRADING VOLUME
IN BILLIONS OF DOLLARS)
*$182.0
$124.9
$94.1 $84.0
$40.6 f6_08 $74.8
1988 1989 1990 1991 1992 1993
Shared Volume 3.2 3.8 4.6 4.3 5.2 *5.5
(in Billions)
*Year-end projection
* Trading volume data is for Depositary Receipts listed on exchanges only.
During the first six months of 1993, this accounted for 231 of tthe total 953 programs.
pretty obvious, there are more listings. The more listings, the
more trading volume. But what I think is more important is that
we have seen a clear trend over the last few years where domestic
portfolio managers - of pension money, mutual funds, etc. -
are starting to invest internationally by using ADRs. They are
not buying shares directly overseas, but their first steps into this
market for traditional domestic portfolio managers will always be
through the ADR mechanism. We also see a lot of retail interest
in ADRs. Approximately 30% of the ADR trading volume is by
retail investors.
This chart below shows some of the most actively traded
ADRs in the United States. About U.S.$16 billion of Royal Dutch
ADRs were traded in the United States last year. One of the
things I always hear is that large institutional investors don't buy
ADRs, that only retail investors buy ADRs. Well, I don't know
about you, but my family clearly does not buy U.S.$15 billion
worth of securities. So the message is that large institutional in-
vestors do buy ADRs and they actively trade ADRs.
For 1993, we are projecting that there will be about thirty-
five public offerings, Level III-type ADRs, which is up signifi-
cantly since 1992. There are a couple of reasons. One is priva-
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TOP 20 SPONSORED DEPOSITARY RECEPTS*
AS OF JUNE 30, 1993
Company
Glaxo Holdings
Telefonos de Mexico Ser L
Royal Dutch Petroleum
Hanson PLC
British Petroleum
Ericsson Telephone
"B" Shares LM
SmithKline Beecham
Wellcome PLC
Memorex Telex
Unilever
Senetek PLC
News Corporation
YPF S.A.
Reuters Holdings
Phillips
Imperial Chemical Industries
TOTAL "B" Shares
Repsol
Telefonica de Espana
Automated Security
(Holdings)
* by Share Volume
Country
U.K.
Mexico
Netherlands
U.K
U.K
Sweden
U.K
U.K
Netherlands
Netherlands
U.K
Australia
Argentina
U.K.
Netherlands
U.K
France
Spain
Spain
U.K
Share
Volume
274,799,000
254,317,200
174,911,200
160,747,800
116,782,000
88,625,500
58,637,400
52,861,600
49,692,800
45,730,700
45,146,100
45,115,700
43,407,400
42,473,300
38,353,100
36,586,300
36,251,800
28,898,900
27,472,200
27,202,800
Dollar
Volume Exchange
$5,253,110,494 NYSE
12,930,880,394 NYSE
15,591,366,306 NYSE
2,879,921,644 NYSE
6,089,377,100 NYSE
3,256,187,231 NASDAQ
1,768,871,875 NYSE
646,370,044 NYSE
22,747,031 NASDAQ
5,028,425,044 NYSE
117,389,408 NASDAQ
1,854,475,500 NYSE
957,675,763 NYSE
2,583,684,525 NASDAQ
532,210,944 NYSE
2,235,510,356 NYSE
848,214,713 NYSE
706,565,350 NYSE
903,727,956 NYSE
128,727,131 NYSE
tizations; many countries around the world are going through a
privatization exercise, selling off their state enterprises and list-
ing their securities around the world. They do that typically
through a public offering in the United States. The other rea-
son is that non-U.S. companies are simply taking advantage of
the favorable markets here in the United States, so they're rais-
ing capital here. And, in many cases, the capital they are raising
here is at a much better cost than it would be in their home
country.
For 1993, we are projecting approximately U.S.$8 billion in
new capital will be raised by non-U.S. companies. Again, that is
up significantly compared to last year. We have also tended to
see the size of the offerings increase over the last year or two. As
I said, YPF raised U.S.$2.3 billion, Wellcome PLC raised U.S.$1.5
billion last year, so some of these offerings are quite big through
ADRs.
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III. RAISING CAPITAL IN U.S. MARKETS
There are essentially two ways a non-U.S. company can raise
capital in the United States: they can make a public offering or
make a private placement under Rule 144A. 10
A. Public Offerings
The advantages of doing a public offering are simple. By
doing a public offering, the company is going to be treated like
any other U.S. company that is traded in the public markets.
These issues are going to have access to the fullest possible inves-
tor base. Finally, there are virtually no restrictions on the resale
of the securities in the United States. So they are taking optimal
advantage of the U.S. public markets by making a public offer-
ing.
However, public offerings are not without their disadvan-
tages. The lead-in time may be prohibitive. As Bill Decker men-
tioned, 1 it can be done in six months; but compare that to a
Rule 144A offering, which can be done in two months or less.
Secondly, costs are higher. Because a public offering re-
quires SEC registration, the cost can be substantial for some
companies, depending on their internal accounting records, ac-
quisitions they have made in the past, etc. You can easily expect
if you are doing a public offering for the bill to run anywhere
between U.S.$500,000 to U.S.$1 million.
Here are some examples of some recent public offerings
dating back to 1988. What I think is most interesting is that after
companies did offerings, their number of ADRs outstanding usu-
ally increased dramatically.
If you look at Vodafone, they did a public offering in 1988
of 4.3 million ADRs. Currently, they have about 25 million ADRs
outstanding, which shows you how much after-market support
there is for the offering.
I used to always hear, "Well, we don't want to enter the U.S.
markets because we're afraid of flowback." Flowback is when a
10. See 17 C.F.R. § 230.144A (1993); see also Decker, supra note 1, at S13 (discuss-
ing public offering, private placement and Rule 144A options for non-U.S. companies);
Jensen, supra note 9, at S29 (discussing public offering and Rule 144A options for non-
U.S. companies).
11. See Decker, supra note 1, at S21 (discussing time-frame for non-U.S. companies
preparing for public offerings in United States).
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SAMPLE PUBLIC OFFERINGS
Dollar
Offer Date Company Amount
10/25/88 Vodafone Group $129,489,000
12/05/88 British Steel 526,050,000
12/08/88 Hong Kong Telecom 123,147,500
05/17/89 Repsol 181,527,500
06/30/89 Anangel-American 56,925,000
07/20/90 Compania de Telfonos 110,163,760
de Chile
06/06/91 Elan 66,000,000
06/13/91 Elf Aquitaine 205,488,000
10/31/91 Total 264,928,000
04/08/92 Empreas ICA 326,485,000
07/27/92 Wellcome PLC 1,086,715,000
05/04/93 Buenos Aires 38,362,500
Embotelladora
07/07/93 YPF S.A. 2,375,000,000
ADRs
Offered
4,338,000
22,500,000
7,037,000
12,650,000
3,450,000
6,499,337
2,000,000
7,200,000
13,600,000
19,205,000
71,260,000
1,650,000
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ADRs
Outstanding
08/01/93
23,434,174
33,911,505
29,066,852
53,032,324
6,710,016
11,899,597
30,254,755
18,379,028
38,566,510
20,875,979
39,676,996
6,608,687
125,000,000 125,694,305
company does a public offering or a private placement in the
United States, and then over a period of time the U.S. investors
sell and all the shares go back into the home country. That's
referred to as flowback. Flowback has not been an issue, has not
been a problem, over the last couple of years for a few reasons.
One is that the investment banks have learned how to better
place their shares so that they're not selling them or underwrit-
ing them to investors who instantly sell them for a profit and sell
the shares back into the home country. Secondly, and probably
more importantly, there is a much bigger investor base now that
is willing to buy non-U.S. securities than there was five years ago.
As a result, after the offering is completed, if an investor wants to
sell his ADRs, rather than canceling them and selling the shares
back in the home country, he simply sells his ADR to another
U.S. investor, so the shares stay in the U.S. marketplace.
B. Private Placement Offerings under Rule 144A
Let me describe Rule 144A in laymen's terms.12 Basically, a
company can make a private placement to Qualified Institu-
tional Buyers ("QIBs") here in the United States. 3 Because it is
12. See 17 C.F.R. § 230.144A (1993); see also Decker, supra note 1, at S14 (discuss-
ing Rule 144A); Jensen, supra note 9, at S35 (discussing Rule 144A).
13. See 17 C.F.R. § 230.144A(a) (1993) (defining "qualified institutional buyer" for
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a private placement the company does not have to register with
the SEC.1 4 They do usually issue an offering memorandum that
describes the company and other factors that are relevant to the
offering, and some financial information as well, but they do not
have to register or conform to U.S. accounting or U.S. disclosure
requirements. 1
5
Once the offering is done and the private placement offer-
ing is completed to these QIBs, the so-called large investors can
trade these 144A depositary receipts among themselves. They
don't have to wait two or three years to get out of it; 6 they're not
restricted in that sense; they can sell their ADRs to another QIB
- or, probably more importantly, under Regulation S,' 7 they
can cancel the ADR and sell the actual shares back into the
home country.
Typically, a 144A offering will be for a company that is not
in a position to register with the SEC in the United States, or is
making a worldwide global offering and simply wants to raise a
small amount of money in the United States. A "small amount
of money" could be anywhere from U.S.$30 to U.S.$50 million.
Once they get past the U.S.$50 million mark, it becomes difficult
to place the shares under 144A, and more than likely the com-
pany will do a public offering if they want to enter the U.S. mar-
ket.
A lot of companies also use Rule 144A as a stepping stone
into the U.S. market. What I mean by that is once a company
does a 144A offering, they can either at a later stage upgrade
through listing a different ADR program on the NYSE, or they
can do what is known as an exchange offer, where essentially
purposes of Rule 144A). Qualified Institutional Buyers under Rule 144A include: in-
surance companies (as defined in section 2(13) of the Securities Act of 1933, 15 U.S.C.
§ 77b(13) (1988)); investment companies (registered under the Investment Company
Act, 15 U.S.C. § 80a (1988)); business development companies (as defined in section
2(a)(48) of the Investment Company Act, 15 U.S.C § 80a-2(48) (1988), or section
202(a) (22) of the Investment Advisers Act of 1940, 15 U.S.C. § 80b-2(a)(22) (1988));
and several other entities and individuals. 17 C.F.R. § 230.144A (1993).
14. See 15 U.S.C. § 77d(2) (1988). Section 77d(2) of the Securities Act of 1933
provides that "[tihe provisions of section 7 7 e [requiring registration] of this title shall
not apply to ... transactions by an issuer not involving any public offering." Id.
15. See Decker, supra note 1, at S14 (discussing preparation of offering circular for
private placement).
16. SeeJensen, supra note 9, at S36 (discussing benefits Rule 144A transactions).
17. 17 C.F.R. §§ 230.901-904 (1993).
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they take their privately placed securities, register them with the
SEC, and the securities become freely traded on one of the ex-
changes.
Private placements under 144A offer an issuer many advan-
tages. First, a placement under 144A involves a relatively short
lead-in time of only a couple of months. Second, 144A private
placements do not require SEC registration, so the cost is sub-
stantially lower than doing a public offering.' 8 I should not say
"substantially lower" any longer. There have been some 144A
deals that have been done where it would have been more cost
advantageous to do a public deal rather than a 144A deal.
There are, however, certain disadvantages to Rule 144A. It
is a private placement; you only can sell your securities to QIBs.
Even though 144A was intended to create a resale market among
these large institutional investors, the fact of the matter is the
market has not developed to the extent that people thought it
would. Companies can use Rule 144A to raise a small amount of
capital, but they are not going to be able to build a trading mar-
ket here under 144A.
One of the innovations that has occurred on this side to
help overcome the shortcomings of a 144A offering, especially as
it relates to restrictions on resales and liquidity, is that now, typi-
cally, companies also establish what is known as a Level I ADR
for the U.S. public markets that trades side-by-side with a 144A
program. You have to be careful when you take this approach
that you have the proper safeguards built into both the Level I
and the 144A facility so that there's no leakage between the two
programs.
In 1993 the 144A market basically died. In 1991 and 1992 it
was pretty substantial. In 1992, about U.S.$3.8 billion was raised
in equity under 144A ADR offerings. This year it is probably go-
ing to be somewhere around U.S.$500 million. The reason is
that companies are learning that if they really want to take ad-
vantage of the U.S. markets, they have to do a public offering.
There are some companies for whom it still makes good
sense to do a 144A offering, but more and more companies are
realizing that, 'Yes, we could raise some money in the United
States, but we're not going to be able to build a liquid market for
18. See supra note 14 and accompanying text (noting that registration is not re-
quired in private placements). .
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144A DEPOSITARY RECEIPT MARKET
1990
Average Capital
Raised per Issue 158.3
($US million)
1991 1992 1993
256 228.6 215.6
0 In the first six months of 1993, there were 5 Depositary Receipt private offerings; 4 of which
were Rule 144A.
our shares here under 144A." So they are doing public offerings
instead.
Here are some sample 144A deals that have happened over
the last couple of years.
SAMPLE 144A TRANSACTIONS
Amt.
Company ($mm)
U.K. Generating Cos. 575
U.K. Regional Electric Cos. .175
Vitro 37
Samsung Electronics 35
STET 25
Grupo Situr 51
Telecom Argentina 270
Australian Consolidated Press 23
Cemex 461
Reliance Industries 150
Asia Cement 61
Roche Holdings 275
Philippine Telephone 316
Woolworths Limited 27
Industry
Utility
Utility
Glass
Electronics
Telecommunications
Hotel/Leisure
Telecommunications
Publishing
Cement
Conglomerate
Cement
Chemical
Telecommunications
Specialty Retailing
Date
12/90
3/91
4/91
5/91
6/91
12/91
3/92
4/92
4/92
5/92
6/92
10/92
10/92
7/93
Type of
DR Offering
U.S. Only
U.S. Only
U.S. Only
Global
U.S. Only
Global
Global
U.S. Only
Global
Global
Global
U.S. Only
Global
Global
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IV. ROLE OF THE DEPOSITARY
The last thing I want to talk to you about is the role of the
depositary. A depositary bank, such as The Bank of New York,
has basically three roles.
First, we act as the depositary bank. That means that we are
responsible for assisting the brokers who trade ADRs - such as
Merrill Lynch, Goldman Sachs, First Boston - in issuing and
canceling ADRs. As I described earlier, when somebody buys
Glaxo shares in London and they decide to issue ADRs, they de-
posit them with The Bank of New York, and we issue the ADRs.
That function is called a depositary function. Those types of
transactions account for about ten to fifteen percent of the trad-
ing volume in ADRs.
Second, the depositary bank basically acts as the non-U.S.
company's transfer agent in the United States. As transfer agent,
the depositary bank is responsible for maintaining shareholder
records, disbursing dividend payments, sending out proxy no-
tices, etc. So the same type of functions we would perform for a
U.S. company as a transfer agent, we perform for a company
with an ADR program.
The last function of the depositary bank is that of an admin-
istrator. Basically, we help the company understand how to
reach U.S. investors and how to promote their securities in the
U.S. market; we help them put on "road shows" in the United
States, i.e. investor presentations; 19 and, more importantly, we
are constantly supplying the company with information regard-
ing their ADR program - which brokers are trading their ADRs,
what price they're trading at, how many ADRs are outstanding,
and who their shareholders are.
CONCLUSION
In conclusion, over the next few years you are going to see
more and more companies enter the U.S. market by using ADRs.
Just as important, more and more U.S. investors will also be buy-
19. See RICHARDJENNINGS ET AL., SECURITIES REGULATION 177 (7th ed., 1992). Dur-
ing the "road show," management and the lead underwriter tour the country making
presentations to educate prospective institutional investors regarding the prospects of
the issuer and the merits of the particular offering. Id.
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ing or starting to diversify their portfolios internationally by us-
ing ADRs. Thank you.
